Trial reportBone marrow transplantation2026
Excellent outcomes using a novel reduced intensity conditioning with thiotepa and post-transplant cyclophosphamide for HLA-matched related donor transplant in adolescents and adults with sickle cell disease.
Trial report in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloablative HLA-matched related donor (MRD) hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment for children with sickle cell disease (SCD), achieving survival rates over 90%. However, optimal conditioning for older SCD patients undergoing MRD transplantation is unknown. We evaluated a novel conditioning regimen comprising thymoglobulin, thiotepa, cyclophosphamide, fludarabine, and total-body irradiation (200 cGy). Graft-versus-host disease (GVHD) prophylaxis included post-transplant cyclophosphamide (100 mg/kg), mycophenolate mofetil, and sirolimus. We aimed to improve donor engraftment rates, decrease GVHD, and minimize toxicity. A total of 25 patients were prospectively recruited in a multicentre study across three sites; 22/25 (88%) were fully matched, and 3/25 (12%) received a one-antigen-mismatched sibling transplant. 12% (3/25) of patients had experienced a second graft failure from a previous HCT. 11 participants (44%) received bone marrow, while 14 (56%) received peripheral blood as stem cell sources. The median age was 26.7 years (IQR, 18.53-32.02), and the median follow-up was 42 months (IQR, 30-49). The estimated 5-year event-free survival rate was 96%, and the 2-year overall survival rate was 100%. No graft failure was observed. Median whole blood chimerism at day +28 and day +365 engraftment was 100% and 97%, respectively. Among evaluable participants, 17/21 (81%) were off immunosuppression at 1-year post-transplant. The 1-year grade III-IV acute GVHD rate was 4% (n = 1), with no chronic GVHD. This regimen produced high engraftment and survival in this cohort using our novel conditioning regimen for MRD HSCT in adolescents and adults with severe SCD, including those undergoing a second HSCT. Optimal donor engraftment is associated with a lower risk of secondary myeloid neoplasms.
Indexed as
Identifiers
42049986What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.